Last updated: 2026-11-14 21:53:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
PharmaCyte Biotech, Inc. (PMCB) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $6.75, with a market capitalization of $4.32M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.51 to $28.69. This page covers its latest market performance, valuation, price trends and company information.
$4.32M | |
$8.17 | |
$8.17 | |
$1.51 | |
$7.64 | |
126.43K | |
13.73K | |
-- | |
$28.69 | |
$1.51 | |
0.46% | |
-- |
PharmaCyte Biotech, Inc. (PMCB) last closed at $6.75 as of 2026-11-14 00:31:00, down 17.49% ($1.43) from the previous close of $7.64.
During the latest regular trading session, PMCB traded between $1.51 and $8.17, with a volume of 126.43K shares. The closing price was near the upper end and near the lower end of its 52-week range.
PMCB is down 17.49% as of the last close.
Over the past seven days, PharmaCyte Biotech, Inc. (PMCB) moved from $7.13 to $6.75, representing a decline of 5.38% ($0.38).
The stock traded between $1.51 and $8.23 during the period. The latest price is near the upper end of the 7-day range, indicating strong downward.
The average daily volume was 34.85 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 19.3%
PMCB is currently trading at $6.75, placing it 19.3% of the way from its 52-week low of $1.51 to its 52-week high of $28.69. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 2 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for PharmaCyte Biotech, Inc.
Stock Split | |
|---|---|
| Split Date | Nov 13, 2026 |
| Split Ratio | 1-for-19 |
Latest news related to PharmaCyte Biotech, Inc. and PMCB stock.
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company") today provided an update on its financial position. As reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended
Eligible investors can buy real shares of PharmaCyte Biotech, Inc. (PMCB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to PMCB, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between PMCB shares and USD.
PMCB Shares to USD
1.00 PMCB shares = 6.745 USD
Calculations are estimates based on the latest available price and are for reference only.
